Table 2 Association of CX3CR1 expression in intraperitoneal lavage fluid with clinicopathological data and operative outcomes

Sex

Male/ Female

24/ 7

7/ 3

0.683

11/ 6

20/ 4

0.270

Age(years-old)

72.0 (69.5-76.0)

69.5 (65.3-77.3)

0.438

69.6 (65.0-73.0)

73.3 (69.0-78.3)

0.295

Tumor size (mm)

45.0 (30.0-80.5)

42.5 (23.0-54.5)

0.523

38.0 (30.0-50.0)

50.0 (33.8-86.3)

0.076

Comorbidities

absent/ present

4/ 27

2/ 8

0.622

3/ 14

3/ 21

0.679

Other cancer history

absent/ present

18/ 13

9/ 1

0.123

12/ 5

15/ 9

0.742

Preoperative NLR

2.66 (1.92-3.39)

1.98 (1.70-3.05)

0.235

1.79 (1.64-3.29)

2.75 (2.19-3.49)

0.037*

Postoperative NLR

6.65 (4.47-9.01)

6.65 (5.44-9.32)

0.574

5.56 (3.81-6.65)

7.38 (5.72-11.7)

0.005*

Preoperative PLR

113 (70.1-137)

78.1 (56.4-104)

0.118

56.0 (51.2-101)

124 (90.2-165)

<0.001*

Postoperative PLR

177 (128-236)

183 (97.1-261)

0.777

99.3 (79.0-174)

191 (175-491)

<0.001*

CRP POD3

12.1 (4.34-19.6)

12.2 (9.92-21.3)

0.649

6.29 (3.24-14.3)

14.2 (10.1-23.8)

0.010*

cT stage^a

T1-2/ 3-4

9/ 22

4/ 6

0.698

7/ 10

6/ 18

0.322

cN stage^a

N0/ 1-3

15/ 16

5/ 5

1

9/ 8

11/ 13

1

cStage^a

Stage I-II/ III-IV

16/ 15

5/ 5

1

8/ 9

13/ 11

0.756

Histological type

differentiated/ undifferentiated

18/ 13

4/ 6

0.469

10/ 7

12/ 12

0.752

pT stage^a

T1-2/ 3-4

10/ 21

6/ 4

0.15

10/ 7

6/ 18

0.051

pN number

2.00 (0.00-3.00)

0.00 (0.00-1.75)

0.361

0.00 (0.00-3.00)

2.00 (0.00-3.00)

0.194

pN stage^a

N0/ 1-3

13/ 18

6/ 4

0.469

11/ 6

8/ 16

0.062

pStage^a

Stage I-II/ III-IV

20/ 11

7/ 3

1

13/ 4

14/ 10

0.321

Lymphatic invasion

absent/ present

16/ 15

7/ 3

0.467

12/ 5

11/ 13

0.201

Venous invasion

absent/ present

17/ 14

7/ 3

0.48

12/ 5

12/ 12

0.217

Operative approach

open/ laparoscopic

25/ 6

6/ 4

0.222

12/ 5

19/ 5

0.714

Operative procedure

DG or PG/ TG

19/ 12

8/ 2

0.447

13/ 4

14/ 10

0.321

Lymphadenectomy

D1 or 1+/ D2

10/ 21

6/ 4

0.150

10/ 7

6/ 18

0.051

Operative time (min)

251 (213-289)

300 (239-324)

0.092

236 (219-306)

261 (225-305)

0.634

Anesthesia time (min)

289 (246-322)

314 (275-369)

0.141

277 (265-331)

296 (264-339)

0.525

Bleeding (mL)

200 (50-380)

440 (35-844)

0.370

80 (20-510)

265 (73-410)

0.283

Comlplications

absent/ present

20/ 11

6/ 4

1

12/ 5

14/ 10

0.519

Duration of hospitalization (days)

13.0 (10-18.5)

12.0 (11-18.3)

0.867

11.0 (9-14)

13.5 (11-21)

0.039*

Adjuvant chemotherapy

absent/ present

13/ 18

6/ 4

0.469

11/ 6

8/ 16

0.062

Recurrence

absent/ present

23/ 8

5/ 5

0.241

15/ 2

13/ 11

0.039*

Recurrent style (local/ lymphatic/ hematogenous/ dissemination)

0/ 2/ 3/ 5

1/ 0/ 1/ 2

0.566

0/ 0/ 0/ 2

1/ 2/ 4/ 5

0.692